Vijayakumar V, Dabbi J M, Walker J L, Mertiri A, Christianson R J, Fiering J
Charles Stark Draper Laboratory, Cambridge, Massachusetts 02139, USA.
Biomicrofluidics. 2022 Oct 20;16(5):054107. doi: 10.1063/5.0109017. eCollection 2022 Sep.
Breakthrough cell therapies for the treatment of cancers require the separation of specific cells, such as T cells, from the patient's blood. Current cell therapy processes rely on magnetic separation, which adds clinical risk and requires elevated manufacturing controls due to the added foreign material that constitutes the magnetic beads. Acoustophoresis, a method that uses ultrasound for cell separation, has demonstrated label-free enrichment of T cells from blood, but residual other lymphocytes limit the ultimate purity of the output T cell product. Here, to increase the specificity of acoustophoresis, we use affinity reagents to conjugate red blood cells with undesired white blood cells, resulting in a cell-cell complex (rosette) of increased acoustic mobility. We achieve up to 99% purity of T cells from blood products, comparable to current standards of magnetic separation, yet without the addition of separation particles.
用于治疗癌症的突破性细胞疗法需要从患者血液中分离出特定细胞,如T细胞。目前的细胞治疗方法依赖于磁分离,这会增加临床风险,并且由于构成磁珠的外来物质的添加,需要加强生产控制。声泳技术是一种利用超声波进行细胞分离的方法,已证明能从血液中无标记富集T细胞,但残留的其他淋巴细胞限制了最终输出T细胞产品的纯度。在此,为了提高声泳技术的特异性,我们使用亲和试剂将红细胞与不需要的白细胞结合,形成声学迁移率增加的细胞-细胞复合物(玫瑰花结)。我们从血液制品中获得了高达99%的T细胞纯度,与目前磁分离的标准相当,但无需添加分离颗粒。